Abstract selected as TOP abstract for Congress Presentation
SEATTLE, May 29, 2024 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced that it will present preclinical data on SRT-015 for severe cholestatic disease during a poster presentation at the European Association for Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024, in Milan, Italy.
"Our data demonstrate the ability of SRT-015 to significantly decrease fibrosis in a model of cholestatic disease with severe fibrosis, supporting its potential as a therapeutic treatment for cholestatic disease including pediatric orphan disease indications," said Neil McDonnell, CEO of Seal Rock Therapeutics. "Collectively with our previous MASH fibrotic efficacy studies, these data show that SRT-015 is a direct and potent antifibrotic in both non-metabolic and metabolic disease models."
Seal Rock Therapeutics is a privately held, clinical stage company based in Seattle focused on developing first-in-class and best-in-class treatments for severe diseases with limited or no available therapies. Seal Rock is led by an experienced management team with a track record of successful drug discovery, development and commercialization. The company's clinical-stage lead product candidate, SRT-015, is a highly optimized, first-in-class ASK1 inhibitorASK1 inhibitor. Seal Rock is also developing preclinical-stage brain-penetrant ASK1/LRRK2 dual kinase inhibitors for treatment of neurodegenerative conditions such as Parkinson's disease and ALS.
For more information, please visit www.sealrocktx.com
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.